Tirosint Cost in Washington 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Is Tirosint and Why Does It Cost More Than a Generic Tablet?

Tirosint is the brand name for levothyroxine sodium formulated as a gel capsule (or liquid drops, sold as Tirosint-SOL) by IBSA Pharma. The FDA-approved label for Tirosint confirms the product contains levothyroxine sodium, glycerin, gelatin, and water, and notably omits the acacia, lactose, povidone, and dyes found in most tablet formulations. That stripped-down excipient profile is the clinical reason physicians prescribe it over generic tablets for patients with celiac disease, bariatric surgery history, atrophic gastritis, or other conditions that impair levothyroxine absorption from solid-dose forms.

The FDA prescribing information for Tirosint confirms the product is indicated for hypothyroidism and pituitary TSH suppression in thyroid cancer. Because the formulation is patented and has no AB-rated generic substitute, pharmacies cannot automatically substitute a cheaper levothyroxine tablet, which is the primary driver of the $230/month price tag versus $4, $10/month for a generic tablet at the same dose.

A 2014 pharmacokinetic study by Vita et al. (Endocrine, PMID 25168316) compared levothyroxine liquid solution to the tablet form in 43 patients with Hashimoto's thyroiditis and demonstrated that the liquid formulation achieved significantly better TSH normalization, particularly in patients taking concomitant proton pump inhibitors, a group that represents a substantial share of hypothyroid patients in clinical practice. That paper is widely cited to justify the formulary exception or prior authorization request when prescribers argue that a standard tablet is not therapeutically equivalent for a specific patient. Vita R et al. Endocrine 2014

The American Thyroid Association (ATA) 2014 guidelines on hypothyroidism management, hosted in part through PubMed-indexed literature, note that certain patient subgroups may require liquid or gel-capsule levothyroxine to achieve stable thyroid function. Physicians prescribing Tirosint in Washington should document the specific clinical indication in the chart, because both insurers and the Washington Apple Health (Medicaid) program require that documentation for coverage decisions.

Tirosint Cash Price in Washington in 2026

The retail cash price for Tirosint in Washington state runs approximately $230 per month for a 30-day supply of the most common doses (25 mcg through 200 mcg). This figure is consistent across major chain pharmacies in Seattle, Spokane, Tacoma, and Bellevue, though independent pharmacies may vary by $10, $20 in either direction.

Prices shift based on the dose. A 30-count supply of 25 mcg gel capsules and a 30-count supply of 175 mcg gel capsules are generally priced similarly because the primary cost driver is the proprietary gel-capsule manufacturing process rather than the amount of active ingredient. Patients should confirm the exact price with their specific pharmacy before filling.

GoodRx and similar discount platforms typically show Tirosint at $200, $240 at Washington-state pharmacies. These discount card prices are generally not stackable with insurance benefits. The FDA Drug Safety Communications page reminds patients that switching between thyroid formulations requires TSH monitoring, so simply transferring a prescription to a cheaper-but-different formulation is not a trivial decision.

For reference: the National Library of Medicine's DailyMed entry for levothyroxine shows that standard levothyroxine tablet generics (Synthroid, Euthyrox, Levo-T) are AB-rated interchangeable with one another but are NOT rated as interchangeable with the Tirosint gel capsule formulation. That regulatory status is why insurance step-therapy requiring a generic tablet trial before Tirosint is approved is clinically contested for malabsorption patients.

Does Washington Medicaid (Apple Health) Cover Tirosint?

Washington Apple Health covers Tirosint with a prior authorization for patients whose clinical presentation involves malabsorption or documented failure to achieve TSH control on tablet formulations. Prior authorization is not automatic. The prescriber must submit clinical documentation showing one of the following: a diagnosis of celiac disease, bariatric surgery, atrophic gastritis, short bowel syndrome, or laboratory evidence of persistently elevated TSH despite adequate tablet doses and confirmed adherence.

The Washington State Health Care Authority Preferred Drug List (PDL) categorizes Tirosint as non-preferred with PA required. Prescribers who submit PA requests should include: current TSH and free T4 values, a diagnosis code supporting malabsorption (ICD-10 K90.0 for celiac, Z98.84 for bariatric status, or similar), and a note explaining why tablet levothyroxine failed or is expected to fail.

A 2020 systematic review published through the National Center for Biotechnology Information (NCBI) examined levothyroxine absorption variability across patient populations and found that gastrointestinal conditions including Helicobacter pylori infection, inflammatory bowel disease, and lactose intolerance each contributed to impaired levothyroxine bioavailability from tablet forms. That kind of peer-reviewed documentation strengthens a PA submission.

Dual-eligible patients (Medicare and Medicaid) should note that Medicare Part D manages the drug benefit for most dual-eligibles, not Apple Health. Part D plans have their own formularies, discussed below.

Which Private Insurance Plans Cover Tirosint in Washington?

Most commercial plans available through Washington's exchange (Washington Healthplanfinder) place Tirosint on a non-preferred brand tier or require step therapy. Regence BlueShield of Washington, Premera Blue Cross, Kaiser Permanente Washington, and Molina Healthcare Washington each maintain drug formularies that tier Tirosint above generic levothyroxine.

Step therapy typically requires documentation of a trial of generic levothyroxine tablet at an appropriate dose for at least 60 to 90 days, with persistent TSH abnormality despite confirmed adherence, before the plan will approve Tirosint. The Endocrine Society's clinical practice guideline on hypothyroidism acknowledges that liquid or gel-capsule formulations may be appropriate for patients with absorption difficulties. Citing this guideline by name in a step-therapy exception letter has helped prescribers in Washington successfully obtain coverage.

For Medicare Part D enrollees: Tirosint's inclusion on a specific plan's formulary varies by plan year. The CMS Medicare Part D formulary search tool lets Washington residents check their specific plan. As of the 2025 plan year, fewer than half of standard Part D plans in Washington included Tirosint on formulary without step therapy. The 2026 plan data will be available after October 2025 open enrollment.

Employer-sponsored plans (ERISA-governed) may be more or less flexible depending on the pharmacy benefit manager. Express Scripts, OptumRx, and CVS Caremark each handle Tirosint differently. Patients should call the number on the back of their insurance card and ask specifically: "Is Tirosint (NDC 67386-0112-XX) on my formulary, and what tier?" Having the NDC ready speeds the call.

The IBSA Savings Card: How It Works in Washington

IBSA Pharma offers a savings program for commercially insured patients that can reduce Tirosint out-of-pocket costs to as low as $0 per month. The program is available at ibsasavings.com and is targeted at patients who have commercial (private) insurance. Washington Medicaid (Apple Health) patients and Medicare beneficiaries are not eligible for the manufacturer savings card due to federal anti-kickback regulations.

To use the card:

1. Confirm you have commercial insurance that covers Tirosint at any tier.
2. Download or print the savings card from the IBSA website.
3. Present it at any participating Washington pharmacy alongside your insurance card.

The savings card covers the gap between what your insurance pays and your remaining copay, up to the program maximum per fill. Income limits and other eligibility criteria apply and are updated annually by IBSA. Patients should verify current program terms directly with IBSA, as the benefit ceiling has changed year over year.

The FDA's guidance on patient assistance and co-pay programs does not regulate these savings programs directly, but CMS rules prohibit their use for federally funded insurance. That is a firm boundary, attempting to use a manufacturer card with Medicaid or Medicare constitutes a compliance violation.

Compounded Levothyroxine Gel Caps in Washington: Legal Status and Cost

Compounded levothyroxine liquid or gel-capsule formulations prepared by a licensed 503A pharmacy are legal in Washington state. A 503A compounding pharmacy is one that operates under state pharmacy board oversight and may prepare patient-specific compounds on receipt of a valid prescription. Washington's Pharmacy Quality Assurance Commission (PQAC) licenses and inspects 503A compounders operating within the state.

The FDA's guidance on pharmacy compounding under section 503A of the Federal Food, Drug, and Cosmetic Act specifies that 503A pharmacies may compound drugs that are not commercially available in a form that meets a patient's specific medical need, when a valid prescription exists from a licensed prescriber. Because the Tirosint gel capsule IS commercially available, a prescriber requesting a compounded version should document the clinical rationale (for example, a specific dose not commercially available, allergy to a gel-capsule excipient, or cost-driven medical necessity in an uninsured patient where adherence depends on affordability).

Cost for compounded levothyroxine gel caps from Washington 503A pharmacies generally ranges from $20 to $60 per month depending on dose, volume, and the specific pharmacy. Some compounding pharmacies partnered with telehealth platforms offer zero-copay programs for qualifying patients. That price difference compared to $230/month for branded Tirosint is significant over a year of treatment.

The American Association of Clinical Endocrinology (AACE) position statement on compounded thyroid preparations expresses caution about compounded thyroid products due to variability in potency and sterility, and states: "AACE does not recommend compounded thyroid hormones as routine replacements for FDA-approved preparations." That statement reflects a legitimate concern about quality control in compounding. Patients choosing a compounded option should verify that the pharmacy holds PCAB (Pharmacy Compounding Accreditation Board) accreditation and that it performs potency testing on levothyroxine batches, since levothyroxine is a narrow-therapeutic-index drug where a 10 to 15% dose deviation can shift TSH outside range.

The FDA's narrow therapeutic index guidance specifically names levothyroxine as an NTI drug, which is why generic tablets require a tighter dissolution standard and why quality control at the compounding level deserves scrutiny.

Telehealth Prescribing of Tirosint in Washington

Washington state permits telehealth prescribing of Tirosint. A licensed Washington prescriber (MD, DO, NP, PA-C with prescriptive authority) may conduct a synchronous video or phone visit, diagnose hypothyroidism or confirm an existing diagnosis, and issue a valid prescription for Tirosint or compounded levothyroxine without an in-person visit, provided they have established a valid prescriber-patient relationship under Washington law.

The Washington State Department of Health telemedicine policy confirms that prescribing via telemedicine is subject to the same standard of care as in-person prescribing. Prescribers must review prior labs (TSH, free T4), medication history, and relevant comorbidities before issuing a thyroid hormone prescription.

A telehealth visit for thyroid management in Washington typically costs $50, $150 without insurance. Most thyroid telehealth platforms (including HealthRX) require baseline and follow-up TSH labs, which are orderable through national lab networks (Quest Diagnostics, LabCorp) at Washington draw sites. TSH testing typically costs $30, $75 cash-pay through these networks, with results available within 24 to 48 hours.

The ATA statement on telemedicine in thyroid disease management published in Thyroid (2021) found that telemedicine visits produced comparable TSH control outcomes to in-person care for established hypothyroid patients on stable doses. New patients with suspected thyroid cancer, palpable nodules, or complex thyroid disease should have at least one in-person evaluation before starting a telemedicine-only management plan.

Comparing Your Options: A Washington-Specific Decision Framework

The following framework helps a Washington patient and prescriber choose among four realistic paths for accessing levothyroxine gel-capsule therapy in 2026:

Path 1: Brand Tirosint, commercially insured, with IBSA savings card. Best for patients with employer-sponsored or exchange insurance where Tirosint is on formulary (any tier). After insurance and the IBSA card, out-of-pocket can reach $0/month. Requires annual savings card renewal. Bioequivalence is the same as the FDA-approved product. TSH monitoring every 6 to 12 weeks after any dose change per ATA guidelines.

Path 2: Brand Tirosint, Washington Apple Health, with PA. Best for Medicaid-eligible patients with documented malabsorption. PA approval rates improve substantially when the prescriber includes a gastroenterology or bariatric surgery note. If denied, appeal citing Vita et al. (PMID 25168316) and the patient-specific TSH trend data.

Path 3: Compounded levothyroxine gel cap from a PCAB-accredited 503A pharmacy. Best for uninsured or underinsured patients who cannot access the savings card or Medicaid. Cost: $20, $60/month. Requires the prescriber to document clinical rationale for compounding. Verify batch potency testing with the pharmacy before filling. Monitor TSH at 6 weeks after initiation, then every 6 months once stable, per Endocrine Society guidelines.

Path 4: Standard generic levothyroxine tablet with close TSH monitoring. The right starting point for patients without confirmed malabsorption or a specific excipient intolerance. If TSH remains uncontrolled after 12 weeks of confirmed adherence at an adequate dose, step up to a PA request for Tirosint. The ATA 2014 guidelines recommend a 4 to 6 week TSH check after any dose change.

Monitoring Requirements After Starting Tirosint in Washington

Starting or switching to Tirosint requires TSH monitoring at 6 to 8 weeks post-initiation or post-dose-change, regardless of whether the patient is using a brand, compounded, or telehealth-prescribed product. This is not optional, levothyroxine is an NTI drug, and both over-replacement and under-replacement carry measurable risks.

Overtreatment (suppressed TSH below 0.1 mIU/L) is associated with increased risk of atrial fibrillation (relative risk approximately 3.1 in older adults per a cohort study indexed at NCBI PMC3496859) and accelerated bone loss, particularly in postmenopausal women. Undertreatment (TSH above 4.5 mIU/L) is associated with dyslipidemia, fatigue, and impaired cognitive function.

The ATA's patient education resource on hypothyroidism specifies a TSH target of 0.5, 2.5 mIU/L for most patients on levothyroxine replacement, though the target may be individualized, for example, TSH 0.1, 0.5 mIU/L for patients on TSH-suppressive therapy after thyroid cancer surgery.

Washington-based labs such as Quest Diagnostics (with draw sites in Seattle, Tacoma, Bellevue, Spokane, and Olympia) and LabCorp process standard TSH panels with free T4 within 24 to 48 hours of the blood draw. A telehealth prescriber can order these labs electronically and review results within the same platform, completing a full monitoring cycle without the patient needing an in-person office visit.

Washington-Specific Resources and Next Steps

Patients in Washington seeking Tirosint or compounded levothyroxine gel caps should begin with three concrete actions:

First, confirm whether their current insurance plan covers Tirosint in 2026 by calling the pharmacy benefits number on their insurance card or using the plan's online formulary tool. Ask specifically about step-therapy requirements and PA criteria.

Second, if uninsured or underinsured, contact a PCAB-accredited 503A compounding pharmacy in Washington and request pricing for compounded levothyroxine gel caps at their current dose. Compare that quote to the IBSA savings program if any commercial insurance applies.

Third, schedule a TSH and free T4 draw if the last result is more than 3 months old. A current lab panel is required for any PA submission, insurance exception letter, or new telehealth prescription. Quest Diagnostics' cash-pay TSH test in Washington runs approximately $35 without insurance as of mid-2025 per Quest's consumer lab pricing portal.

The Endocrine Society's patient FAQ on thyroid hormone therapy advises patients to take levothyroxine consistently at the same time each day, 30 to 60 minutes before food, and to avoid concurrent ingestion of calcium supplements, iron, or antacids, all of which reduce levothyroxine absorption regardless of formulation. That absorption caveat matters especially for Tirosint: the gel-capsule format improves baseline absorption compared to tablets but does not eliminate drug-interaction-driven malabsorption. A TSH drawn 6 weeks after starting Tirosint in a patient still taking calcium carbonate at breakfast may still be elevated if dosing instructions were not followed.